Table 3.
Rating scale score changes between treatment groups
| Variable | EGb 761 (n = 25) | AChEI (n = 26) | EGb 761+AChEI (n = 26) | p-value ANCOVA |
|---|---|---|---|---|
| MMSE (T0) | 20.80±2.22 | 21.04±1.91 | 20.85±2.57 | 0.922 |
| MMSE (T1) | 21.72±2.03 | 21.62±2.14 | 23.27±1.18 | 0.002 |
| MMSE (T2) | 22.20±2.10 | 22.31±2.31 | 24.31±1.32 | < 0.0001 |
| RAVLT (T0) | 18.52±2.89 | 18.46±3.29 | 18.42±2.76 | 0.993 |
| RAVLT (T1) | 18.96±2.75 | 18.92±3.04 | 18.50±2.53 | 0.805 |
| RAVLT (T2) | 19.88±2.45 | 20.00±2.86 | 22.23±2.89 | 0.002 |
| CFT (T0) | 8.52±0.92 | 8.38±0.75 | 8.58±1.14 | 0.756 |
| CFT (T1) | 9.84±1.79 | 8.65±0.89 | 9.04±0.99 | 0.005 |
| CFT (T2) | 12.36±1.49 | 10.62±1.17 | 11.77±1.53 | < 0.0001 |
| LFT (T0) | 8.76±1.05 | 8.77±1.03 | 8.88±1.24 | 0.905 |
| LFT (T1) | 9.68±1.21 | 9.85±1.29 | 10.12±1.53 | 0.513 |
| LFT (T2) | 11.44±1.58 | 10.96±1.37 | 11.88±1.79 | 0.120 |
| TMTA (T0) | 161.64±25.13 | 165.62±21.59 | 164.35±21.80 | 0.819 |
| TMTA (T1) | 150.20±24.80 | 162.42±24.73 | 151.08±22.11 | 0.130 |
| TMTA (T2) | 140.32±23.99 | 158.23±27.38 | 138.31±20.96 | 0.007 |
| TMTB (T0) | 248.00±29.35 | 234.15±30.49 | 245.08±26.27 | 0.201 |
| TMTB (T1) | 196.84±35.03 | 191.23±39.76 | 195.15±26.11 | 0.833 |
| TMTB (T2) | 162.52±32.01 | 183.77±41.09 | 137.27±14.01 | < 0.0001 |
| SDMT (T0) | 21.04±10.59 | 22.08±7.28 | 22.23±9.59 | 0.883 |
| SDMT (T1) | 28.28±9.83 | 28.15±8.36 | 23.42±10.40 | 0.122 |
| SDMT (T2) | 35.00±7.86 | 35.54±8.33 | 29.38±11.37 | 0.037 |
| BNT (T0) | 9.20±2.31 | 8.27±2.89 | 9.23±2.97 | 0.364 |
| BNT (T1) | 10.80±1.50 | 10.81±1.17 | 11.12±1.48 | 0.650 |
| BNT (T2) | 12.36±1.32 | 12.27±1.12 | 11.85±1.29 | 0.292 |
| NPI (T0) | 25.48±6.75 | 27.85±7.39 | 28.19±6.38 | 0.315 |
| NPI (T1) | 15.80±6.02 | 21.54±5.60 | 14.85±4.78 | < 0.0001 |
| NPI (T2) | 10.80±5.59 | 16.69±4.48 | 9.92±3.25 | < 0.0001 |
| IDDD (T0) | 48.44±10.94 | 52.81±13.32 | 51.50±10.81 | 0.402 |
| IDDD (T1) | 47.32±10.29 | 50.96±10.25 | 52.46±13.46 | 0.265 |
| IDDD (T2) | 49.20±11.88 | 55.00±14.02 | 51.50±10.16 | 0.234 |
Values are mean ± SD
T0 baseline, T1 follow-up 6 months, T2 follow-up 12 months;
ANCOVA analysis of covariance, BNT Boston Naming Test, CFT Category Fluency Test, χ2 Chi-square, IDDD Interview for Deterioration in Daily Living Activities in Dementia, LFT Letter Fluency Test, MMSE Mini Mental State Examination, NPI Neuropsychiatric Inventory, RAVLT Rey Auditory Verbal Learning Test, SDMT Symbol Digit Modalities Test, TMTA Trail Making Test part A, TMTB Trail Making Test part B